Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results From Two Phase 3 Studies and Their Open-Label Extension

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.